All In Biotech

Drug Trial Radar · NCT06589830

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

A Phase 2 Study to Evaluate TL938 Combined With Trastuzumab in Patients With HER2-Positive Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

May 13, 2025

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Teligene USIndustry
Sponsor type
Industry
Collaborators
Suzhou Teligene Ltd.
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study evaluates TL938 alone or in combination with trastuzumab in patients with HER2-positive advanced colorectal cancer. Cohort 1 determines the recommended Phase 2 dose of TL938 with trastuzumab. Cohorts 2 and 3 evaluate the efficacy and safety of TL938 with trastuzumab or TL938 alone at that dose.

Conditions

  • Colorectal Cancer Metastatic
  • Advanced Colorectal Cancer

Interventions

  • TL938 CapsulesDrug

    Oral administration

  • TrastuzumabDrug

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity, maximum tolerated dose, and recommended phase 2 doseTime frame: Pre-dose up to approximately 24 months post-dose
  2. Objective Response Rate (ORR) by IRCTime frame: Pre-dose up to approximately 24 months post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.